Clinical Trials

Find a Clinical Trial

Enrolling Trials

1-10  of  169
►
A Phase III Clinical Trail to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of ZOSTAVAX in Subjects 50 to 59 Years of Age
Infectious Disease
Vaccine
Adult
This phase II trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back or do not respond to treatment and have spread to other places in the body. Ensartinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MMC - Eau Claire
2310 Craig Rd
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - River Region at Stevens Point
4100 State Highway 66
Stevens Point, WI 54482
MMC - Weston
3400 Ministry Parkway
WESTON, WI 54476
zzzMerrill Center
1205 O'DAY STREET
MERRILL, WI 54452
►
ICH A Phase III Randomized, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10mg Compared to Placebo, in Patients with Chronic Heart Failure with Preserved Ejection Fraction (HFpEF)
Cardiology
Adult
The purpose of this study is to investigate the clinical efficacy and safety of empagliflozin in treating subjects who have a type of chronic heart failure that includes preserved ejection fraction. This study will see if empagliflozin can reduce hospitalizations related to heart failure and cardiac associated death compared to placebo in subjects with heart failure receiving appropriate care.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
►
Assessment of Assay for Rapid Identification of Borrelia from Whole Blood
Infectious Disease
Adult
The study objectives are to address the need for accurate and rapid Borrelia detection and identification, the Sponsor intends to extend the utility of its direct-from-specimen molecular diagnostic platform, RaPID (Resistance and Pathogen IDentification), to facilitate ultra-sensitive, direct detection of Borrelia from whole-blood. RaPID, leverages proprietary duplex DNA invading artificial nucleic acids and provides direct-from-sample results in roughly 3 hours. The objective of this study is to provide samples sufficient for research and development needs for HelixBind's RaPID/LD assay.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
►
ICH - A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of Rebiotix RBX2660 (microbiota suspension) for the Prevention of Recurrent Clostridium difficle Infection
Infectious Disease
Adult
The purpose of this study is to learn about the safety of RBX2660 and whether it is effective in preventing recurrent Clostridium difficile infection (CDI).
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
►
A Phase IIIB, Observer-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine when Administered Concomitantly with Routine Vaccines to Healthy Infants
Vaccine
Child
The purpose of this study is to assess the immune response against those strains and the safety of rMENB+OMVNZ vaccine when administered concomitantly with the 13-valent pneumococcal conjugate vaccine (PCV 13) and other US Advisory Committee on Immunization Practices (ACIP) recommended routine infant vaccines.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
►
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 1703; Progress III); Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (BMT CTN 1801; Mi-Immune)
1703: Graft-versus-Host Disease (GVHD) is a complication that affects many hematopoietic stem cell transplant (HSCT) patients; it occurs when the new cells from a transplant attack the recipient's body. The current standard GVHD prophylaxis regimen for patients with hematologic malignancies undergoing HSCT involves a combination of immunosuppressive agents given for the first 6 months after transplant. The standard strategy of Tacrolimus/Methotrexate will be used as a control arm in comparison to one other treatment plan utilizing Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide. Study participants will receive an infusion of mobilized peripheral blood stem cell grafts on both arms. Study participants will be randomized to one of these two treatment arms. 1801: A relationship between the intestinal microbiota and graft-versus-host disease (GVHD) has long been appreciated but is still not well understood. Mice transplanted in germ-free conditions or treated with gut-decontaminating antibiotics developed less severe GVHD. Clinical studies initially suggested a benefit from near-total bacterial decontamination, but later showed no clear benefit and this approach was discontinued in the early 1990s. Partial gut decontamination continues to be practiced at many centers. More recently, the advent of next-generation sequencing (NGS) has resulted in cheaper and easier characterization of complex microbial mixtures. This has led to a renewed interest in evaluating the relationship between the microbiota and human health and disease, including recipients of hematopoietic cell transplantation (HCT). Similarly, NGS has also contributed to significant advancements in the investigator's understanding of immune reconstitution in HCT patients and how this may impact clinica outcomes. The goal of this protocol is to test the primary hypothesis that the engraftment stool microbiome diversity predicts one-year non-relapse mortality in patients undergoing reduced intensity allogeneic HCT.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
►
CIRB, Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Cancer Symptom Management
Adult
qatest
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
MMC - Ladysmith
906 College Ave W
Ladysmith, WI 54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9576 Highway 70
MINOCQUA, WI 54548
MMC - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - Weston
3400 Ministry Parkway
WESTON, WI 54476
zzzMarshfield Clinic Cancer Care At St Michaels
900 ILLINOIS AVE
STEVENS POINT, WI 54481
zzzMfld Clinic Cancer Care at Sacred Heart Hospita
900 W CLAIREMONT AVE
EAU CLAIRE, WI 54701
►
CIRB, A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial...
Breast
Cancer Symptom Management
Adult
The purpose of this study is to perform further clinical, dental, biochemical, family, genetic and imaging evaluation of adults with persistent hypophosphatasemia who also harbor pathogenic, likely pathogenic or ALPL variants of uncertain significance and/or have elevated ALP substrates to more fully characterize this cohort and to determine what proportion may have previously unrecognized adult HPP.
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
MMC - Ladysmith
906 College Ave W
Ladysmith, WI 54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9576 Highway 70
MINOCQUA, WI 54548
MMC - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - River Region at Stevens Point
4100 State Highway 66
Stevens Point, WI 54482
MMC - Weston
3400 Ministry Parkway
WESTON, WI 54476
zzzMfld Clinic Cancer Care at Sacred Heart Hospita
900 W CLAIREMONT AVE
EAU CLAIRE, WI 54701
►
CIRB, A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
Germ Cell Tumors
Stem Cell Transplant
Adult
Abstract TBD
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9576 Highway 70
MINOCQUA, WI 54548
MMC - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - River Region at Stevens Point
4100 State Highway 66
Stevens Point, WI 54482
MMC - Weston
3400 Ministry Parkway
WESTON, WI 54476
zzzMarshfield Medical Center
611 Saint Joseph Ave
Marshfield, WI 54449
zzzMfld Clinic Cancer Care at Sacred Heart Hospita
900 W CLAIREMONT AVE
EAU CLAIRE, WI 54701
►
CIRB, Phase III Randomized Adjuvant study of MK-3475 (Pembrolizumab) in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Genitourinary
Adult
0401 - Test Velos Only Insert Personnel 30401 - Test Velos Only Insert Personnel 30401 - Test Velos Only Insert Personnel 30401 - Test Velos Only Insert Personnel 3
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Ladysmith
906 College Ave W
Ladysmith, WI 54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9576 Highway 70
MINOCQUA, WI 54548
MMC - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - River Region at Stevens Point
4100 State Highway 66
Stevens Point, WI 54482
MMC - Weston
3400 Ministry Parkway
WESTON, WI 54476